Publications by authors named "Shumeng Fu"

Claim this Profile
P
Population pharmacokinetics and dosing optimization of cefoselis in paediatric patients with haematological malignancies.
Jing-Rui Liu, Shu-Meng Fu, Totsapol Jirasomprasert, Bo-Hao Tang, Zi-Xuan Guo

J Antimicrob Chemother· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Membrane-targeted molecular binding and redox collapse underlie UV-328 toxicity in Chlorella pyrenoidosa.
Lukuan Huang, Siyu Zhang, Qinghua Ma, Shumeng Fu, Danyang Zou

J Hazard Mater· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Model-informed drug development in public health emergency of international concern: accelerating marketing authorization of simnotrelvir.
Bu-Fan Yao, Yang Yang, Shan-Sen Xu, Bo-Hao Tang, Jia Chen, Shu-Meng Fu

Antimicrob Agents Chemother· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enantioselective Effects of Napropamide on Nutrient-Mediated Secondary Metabolite Biosynthesis and Cadmium Accumulation in Plants.
Ran Wu, Minghui Xie, Shumeng Fu, Lukuan Huang, Mingtong Ge

J Agric Food Chem· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Machine learning approach for dosage individualization of azithromycin in children with community-acquired pneumonia.
Bo-Hao Tang, Shu-Meng Fu, Li-Yuan Tian, Xin-Fang Zhang, Bu-Fan Yao

Br J Clin Pharmacol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimal use of β-lactams in neonates: machine learning-based clinical decision support system.
Bo-Hao Tang, Bu-Fan Yao, Wei Zhang, Xin-Fang Zhang, Shu-Meng Fu

EBioMedicine· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Machine Learning Approach in Dosage Individualization of Isoniazid for Tuberculosis.
Bo-Hao Tang, Xin-Fang Zhang, Shu-Meng Fu, Bu-Fan Yao, Wei Zhang

Clin Pharmacokinet· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A first-in-human phase 1 study of simnotrelvir, a 3CL-like protease inhibitor for treatment of COVID-19, in healthy adult subjects.
Xin-Mei Yang, Yang Yang, Bu-Fan Yao, Pan-Pan Ye, Yan Xu, Fu-Rong Zhao, Shu-Meng Fu

Eur J Pharm Sci· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis